Both prostate carcinoma and benign prostatic hypertrophy are considered to arise from the aberrant proliferation of prostate stem cells.
Murine prostate stem cell antigen.
BMI1 is a regulator of prostate stem cell self-renewal and malignant transformation (Lukacs et al., 2010).
Dendrimers capped with amino groups (DEN) are grafted to graphene oxide (GO) nanosheets for subsequent functionalization of GO with gadolinium diethylene triamine pentaacetate (Gd-DTPA) and prostate stem cell antigen (PSCA) monoclonal antibody (mAb).
Recent studies have implicated the tumor microenvironment in prostate tumorigenesis and have identified putative prostate stem cells in adult tissue.
Adult prostate stem cell biology is highly analogous to the biology of the developing prostate from embryonic prostate stem cells, and understanding the pathways that govern normal prostate development lends insight into the pathways that maintain adult prostate stem cells and prostate cancer stem/progenitor cells.
Animal studies showed excellent imaging capabilities of 124I and 18F minibodies binding to the prostate stem cell antigen (PSCA) [28, 29].
Prostate stem cell antigen (PSCA), a glycosylphosphatidylinositol (GPI -anchored cell surface GPI -anchored is highly expressed in both locelland metasurfaceprostate cancer (CaP).
Cells with a protein marker called CD117+, not previously associated with prostate stem cells, proliferated after castration and testosterone injection, the researchers found.
Y-27632 treatment suppresses apoptosis and increases the cloning efficiency of prostate stem cells.
A distinct transcriptional expression pattern derived from the prostate stem cell niche cell population is manifest by 3,062 transcripts that are exclusively altered in the prostate stem cell niche (Prostate-only cluster).
